The NATIONAL PHARMACEUTICAL COUNCIL (NPC) is the credible and trusted voice of

the biopharmaceutical industry on the critical issues of evidence, the value of medicines for
patients, and innovation.
OUR MISSION
NPCs overarching mission is to sponsor, participate in, and promote scientic analyses
of the appropriate use of biopharmaceuticals, and the clinical and economic value of
improved health outcomes through medical innovation. NPCs strategic focus is on
comparative eectiveness research and evidence-based medicine for health care decision
making, to ensure that patients have access to high-quality care. NPC actively participates
with a variety of health care stakeholders to demonstrate and communicate the value of
biopharmaceuticals and vaccines though practical, evidence-based applications and tools.
NPC is dedicated to:
l Promoting the clinical and economic value of improved health outcomes through
pharmaceutical innovation;
l Contributing to practical solutions that ensure patients have access to and make
appropriate use of prescription medicines;
l Improving health care decision making by expanding the foundation of evidence for
patients and providers to choose treatment options that provide the best clinical value;
and
l Advancing research on the appropriate role of prescription medicines in treating patients.
www.npcnow.org
1894 Preston White Drive
Reston, VA 20191-5433
1501 M Street, NW
Suite 650
Washington, DC 20005
Phone: 703.620.6390
Fax: 703.476.0904
www.npcnow.org
Follow NPC on Twitter @npcnow
Patients
Additional resources available online contain a wealth of information
about the biopharmaceutical industrys most pressing issues.
V
a
l
u
e
I
n
n
o
v
a
t
i
o
n
E
v
i
d
e
n
c
e
www.npcnow.org

website includes a research
and publications library
daily electronic CER update
monthly electronic newsletter
The NATIONAL PHARMACEUTICAL COUNCIL (NPC) is the credible and trusted voice of
the biopharmaceutical industry on the critical issues of evidence, the value of medicines for
patients, and innovation.
OUR MISSION
NPCs overarching mission is to sponsor, participate in, and promote scientic analyses
of the appropriate use of biopharmaceuticals, and the clinical and economic value of
improved health outcomes through medical innovation. NPCs strategic focus is on
comparative eectiveness research and evidence-based medicine for health care decision
making, to ensure that patients have access to high-quality care. NPC actively participates
with a variety of health care stakeholders to demonstrate and communicate the value of
biopharmaceuticals and vaccines though practical, evidence-based applications and tools.
NPC is dedicated to:
l Promoting the clinical and economic value of improved health outcomes through
pharmaceutical innovation;
l Contributing to practical solutions that ensure patients have access to and make
appropriate use of prescription medicines;
l Improving health care decision making by expanding the foundation of evidence for
patients and providers to choose treatment options that provide the best clinical value;
and
l Advancing research on the appropriate role of prescription medicines in treating patients.
www.npcnow.org
1894 Preston White Drive
Reston, VA 20191-5433
1501 M Street, NW
Suite 650
Washington, DC 20005
Phone: 703.620.6390
Fax: 703.476.0904
www.npcnow.org
Follow NPC on Twitter @npcnow
Patients
Additional resources available online contain a wealth of information
about the biopharmaceutical industrys most pressing issues.
V
a
l
u
e
I
n
n
o
v
a
t
i
o
n
E
v
i
d
e
n
c
e
www.npcnow.org

website includes a research
and publications library
daily electronic CER update
monthly electronic newsletter

www.npcnow.org
In shaping NPCs research agenda and professional
programming, we access the expertise of health outcomes
researchers, clinicians, market experts, and other industry
leaders. The resulting research and educational events
demonstrate how the appropriate use of biopharmaceuticals
improves both patient treatment and cost outcomes in the
overall health care environment. Our work informs and
supports public and private sector organizations, as well as
eorts to establish and fund a national research agenda.
In carrying out our patient-centric mandate, NPC engages
with a targeted range of stakeholders, focusing on research
standards and methods for evidence generation, interpretation,
and application that will improve patient outcomes while
sustaining and enhancing innovation and the value of
biopharmaceuticals. We collaborate with leading scientic
policy experts from across key health care sectors toward that
goal.
Over the years, we have actively responded to changes in the
biopharmaceutical environment and contributed to informative
research in this arena. As we look to the future, NPC will
continue to anticipate the issues, produce strong, evidence-
based research and education, build new partnerships, and
demonstrate the benets of new medicines to patients and to
society.
Robust Research Agenda
Since its founding more than half a century ago, NPC has
supported a robust research agenda. Over the years the
issues we have focused on have evolved along with changes
and developments in the health care environment and the
biopharmaceutical industry.
NPC believes strongly in the importance of fostering an
environment that sustains and enhances innovation. This
focus on innovation cuts across all streams of NPC-sponsored
research.
Recent research has focused on many of the issues related to
comparative eectiveness research (CER) and building toward
an optimal future for CER. We have compiled much of that
research in a CER Toolkit, which includes information about
the Patient-Centered Outcomes Research Institute (PCORI),
the National Institute for Health and Clinical Excellence (NICE),
as well as The Good ReseArch for Comparative Eectiveness
(GRACE) principles and other documents and studies
examining CER.
NPC also has undertaken studies examining the issues
surrounding ways to ensure more value from medicines.
We are conducting scientic analyses that will enhance
understanding of the overall clinical and economic value
of prescription medications and the contributions of those
medications to improved health and productivity among
patients. Examples include recent studies on Value-Based
Insurance Design, and Health and Productivity as a Business
Strategy, which help employers realize the best value for their
health investments.
NPC-sponsored research publications are available online at
www.npcnow.org/research.
Topical Educational Events
NPCs professional programming advances the public dialogue
by drawing on the biopharmaceutical industrys science
base and expertise as a resource for reducing uncertainty in
care decisions and improving outcomes for patients. Topical
educational events seek to introduce the industrys perspective
and expertise to inform the discussion and generate
momentum around key issues. NPCs Annual Forum, held
each fall in Washington, DC, is a substantive program on issues
of interest to the biopharmaceutical industry and a variety of
health care stakeholders, including patients, clinicians, payers
and policy makers.

NPC educational events include:
Town Hall Meetingsexplore emerging issues of importance
to the biopharmaceutical industry, such as CER and quality
measure development and use, and help member companies
and other health care stakeholders better understand and
translate research ndings into everyday life; some are
videotaped and made available to member companies as
educational tools;
Corporate Roundtablesbrief member companies and key
stakeholders on industry issues, emerging trends, and related
research;
Forums/Symposiumsfeature recognized health care and
biopharmaceutical industry leaders. Recent events include
NPCs Shaping Convergent Strategies in CER: a CER brieng
co-sponsored with Health Aairs; and NPC-sponsored
workshops and symposia on the evaluation, dissemination
and interpretation of CER at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Annual
International Meeting.
NPC often works in partnership with other organizations
among them the Center for Medical Technology Policy
(CMTP), Pragmatic Approaches to Comparative Eectiveness
(PACE), and the Institute for Clinical and Economic Review
(ICER)to contribute strategic and scientic input on critical
issues such as CER. And NPC researchers, members, and sta
also play a key role on professional educational programs
sponsored by other organizations addressing important
stakeholder issues, including the US Chamber of Commerce,
the Health Industry Forum, the National Health Council, and
the Translational Medical Alliance.
OUR APPROACH
NPC is a policy research organization dedicated to the advancement of
good evidence and science, and to fostering an environment in the United
States that supports medical innovation.
NPC focuses on research development, information dissemination,
education and promotion of the critical issues of evidence, innovation and
the value of medicines for patients. The issues we select for examination
and the researchers and academics we partner with position NPC as a
uniquely credible and trusted voice in the biopharmaceutical research and
health policy communities.
NPC is working to:
l Ensure that sound evidence is recognized by independent experts,
considered appropriately by private and public payers, reected
adequately in benet designs, and incorporated into clinical practice;
l Demonstrate and promote the contribution of innovative medicines to
optimizing health and wellness for patients and the entire health care
system through scientic analyses and fact-based communications;
l Maintain a focus on the issues related to advancing the science and
research aspects of the biopharmaceutical industry and preserving and
improving an environment supportive of innovation.
1950s 1960s 1970s 1980s 1990s 2000s 2010s/NPC Now
National Pharmaceutical Council
incorporates in New York City (1953)
NPC focuses on educating states about
the problem of unauthorized substitution
of non-FDA-approved products at the
pharmacy level
NPC launches annual pharmacy
internship program with American
Pharmacists Association (1959)

NPC develops Compilation on State
Welfare Drug Programs, which would
later become the annual Pharmaceutical
Benets Under State Medical Assistance
Programs (1963)
NPC moves its headquarters to the
metropolitan Washington, DC area
(1965)
NPC works with states to
examine open drug programs
versus closed formularies;
electronic data processing
systems developed through
this eort were later adapted
by the federal government
and acknowledged in the
publication, Medicaid
Management Information
System
As non-FDA-approved drugs remain a
factor, NPC expands educational eorts
with consumer organizations, medical
and pharmacy students and their related
organizations, and federal agencies
NPC sponsors rst national symposium
on the issue of medication compliance,
featuring then Surgeon General C.
Everett Koop; produces several major
publications and develops widely viewed
public service announcement with
professional tennis player Arthur Ashe
focusing on noncompliance
NPC hosts educational forums to
increase public awareness and
understanding of pharmaceuticals, the
industry, and related issues; to assist
member companies in speaking about
the value of pharmaceuticals, produces
video, Spread the Word, that
receives a Telly Award for excellence in
communications (1993)
NPC launches Managed Care Health
Outcomes Project; ndings suggest
that closed formulary restrictions might
have unintended consequences on the
quality of health outcomes (1996)
NPC hosts rst annual member forum
(1999)
NPC develops research papers focusing
on the contribution of new drugs to
improved health and reduced medical
spending, and on the clinical needs of
subpopulations
NPC launches educational project, Your
Pharmacy Benet, to help consumers
understand, choose and use the
pharmacy benets under private
insurance and Medicare Part D (2006)
NPC turns focus to evidence-based
medicine and comparative eectiveness
research issues; grows sta resources to
address new industry challenges (2007)
NPC continues to expand research
portfolio, partnerships, and unique
capacities in the areas of evidence, value
and innovation
More Than Half a Century of Expertise
NPC Leadership
NPC leadership and sta bring a variety of experience from
within the biopharmaceutical industry, government, health
and regulatory agencies, academia, and advocacy groups to
our work.
Dan Leonard, President, leads NPC in bringing
the biopharmaceutical industrys technical
expertise and applied scientic knowledge to
considerations of evidence-based medicine,
comparative eectiveness reviews, evaluation
and application. A veteran association executive
and communications strategist with more than 20 years
of experience in strategic communications, legislative
management, politics and broadcast journalism, his previous
health care industry experience includes serving as executive
vice president of advocacy and professional services for
Americas Health Insurance Plans (AHIP). He received his
bachelors degree in journalism from Marietta College and a
masters in government from Johns Hopkins University. He
currently serves on several boards and industry committees,
including the Pharmacy and Therapeutics Society, the National
Health Council, and the Health Industry Forum.
Robert W. Dubois, MD, PhD, Chief Science
Ocer, oversees NPCs research on policy issues
related to the harmonization, dissemination, and
communication of comparative eectiveness
research, as well as on how health outcomes are
valued. Dr. Dubois is board certied in internal
medicine and brings more than 25 years of experience in
health services research and comparative clinical eectiveness.
He has co-founded and led health care research organizations
in developing quality research with practical application.
Most recently, he was the chief medical ocer at Cerner
LifeSciences, where he focused on comparative eectiveness
and the use of an electronic health records infrastructure to
implement clinical change. He has authored more than 100
peer-reviewed articles on comparative eectiveness, evidence-
based medicine, the development of practice guidelines, and
the optimal use of high cost medical services. Dr. Dubois
received his AB from Harvard College, his MD from the Johns
Hopkins School of Medicine and his PhD in Health Policy
from the RAND Graduate School.
Patricia L. Adams, Vice President, Business
Operations and External Aairs, is responsible
for the overall operations of NPC, including
member relations, external aairs, educational
programs, and communications. Ms. Adams
works closely with the NPC President and the
scientic sta to ensure the smooth operation of research
activities and educational programs for public and private
payers and health policy makers.

www.npcnow.org
In shaping NPCs research agenda and professional
programming, we access the expertise of health outcomes
researchers, clinicians, market experts, and other industry
leaders. The resulting research and educational events
demonstrate how the appropriate use of biopharmaceuticals
improves both patient treatment and cost outcomes in the
overall health care environment. Our work informs and
supports public and private sector organizations, as well as
eorts to establish and fund a national research agenda.
In carrying out our patient-centric mandate, NPC engages
with a targeted range of stakeholders, focusing on research
standards and methods for evidence generation, interpretation,
and application that will improve patient outcomes while
sustaining and enhancing innovation and the value of
biopharmaceuticals. We collaborate with leading scientic
policy experts from across key health care sectors toward that
goal.
Over the years, we have actively responded to changes in the
biopharmaceutical environment and contributed to informative
research in this arena. As we look to the future, NPC will
continue to anticipate the issues, produce strong, evidence-
based research and education, build new partnerships, and
demonstrate the benets of new medicines to patients and to
society.
Robust Research Agenda
Since its founding more than half a century ago, NPC has
supported a robust research agenda. Over the years the
issues we have focused on have evolved along with changes
and developments in the health care environment and the
biopharmaceutical industry.
NPC believes strongly in the importance of fostering an
environment that sustains and enhances innovation. This
focus on innovation cuts across all streams of NPC-sponsored
research.
Recent research has focused on many of the issues related to
comparative eectiveness research (CER) and building toward
an optimal future for CER. We have compiled much of that
research in a CER Toolkit, which includes information about
the Patient-Centered Outcomes Research Institute (PCORI),
the National Institute for Health and Clinical Excellence (NICE),
as well as The Good ReseArch for Comparative Eectiveness
(GRACE) principles and other documents and studies
examining CER.
NPC also has undertaken studies examining the issues
surrounding ways to ensure more value from medicines.
We are conducting scientic analyses that will enhance
understanding of the overall clinical and economic value
of prescription medications and the contributions of those
medications to improved health and productivity among
patients. Examples include recent studies on Value-Based
Insurance Design, and Health and Productivity as a Business
Strategy, which help employers realize the best value for their
health investments.
NPC-sponsored research publications are available online at
www.npcnow.org/research.
Topical Educational Events
NPCs professional programming advances the public dialogue
by drawing on the biopharmaceutical industrys science
base and expertise as a resource for reducing uncertainty in
care decisions and improving outcomes for patients. Topical
educational events seek to introduce the industrys perspective
and expertise to inform the discussion and generate
momentum around key issues. NPCs Annual Forum, held
each fall in Washington, DC, is a substantive program on issues
of interest to the biopharmaceutical industry and a variety of
health care stakeholders, including patients, clinicians, payers
and policy makers.

NPC educational events include:
Town Hall Meetingsexplore emerging issues of importance
to the biopharmaceutical industry, such as CER and quality
measure development and use, and help member companies
and other health care stakeholders better understand and
translate research ndings into everyday life; some are
videotaped and made available to member companies as
educational tools;
Corporate Roundtablesbrief member companies and key
stakeholders on industry issues, emerging trends, and related
research;
Forums/Symposiumsfeature recognized health care and
biopharmaceutical industry leaders. Recent events include
NPCs Shaping Convergent Strategies in CER: a CER brieng
co-sponsored with Health Aairs; and NPC-sponsored
workshops and symposia on the evaluation, dissemination
and interpretation of CER at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Annual
International Meeting.
NPC often works in partnership with other organizations
among them the Center for Medical Technology Policy
(CMTP), Pragmatic Approaches to Comparative Eectiveness
(PACE), and the Institute for Clinical and Economic Review
(ICER)to contribute strategic and scientic input on critical
issues such as CER. And NPC researchers, members, and sta
also play a key role on professional educational programs
sponsored by other organizations addressing important
stakeholder issues, including the US Chamber of Commerce,
the Health Industry Forum, the National Health Council, and
the Translational Medical Alliance.
OUR APPROACH
NPC is a policy research organization dedicated to the advancement of
good evidence and science, and to fostering an environment in the United
States that supports medical innovation.
NPC focuses on research development, information dissemination,
education and promotion of the critical issues of evidence, innovation and
the value of medicines for patients. The issues we select for examination
and the researchers and academics we partner with position NPC as a
uniquely credible and trusted voice in the biopharmaceutical research and
health policy communities.
NPC is working to:
l Ensure that sound evidence is recognized by independent experts,
considered appropriately by private and public payers, reected
adequately in benet designs, and incorporated into clinical practice;
l Demonstrate and promote the contribution of innovative medicines to
optimizing health and wellness for patients and the entire health care
system through scientic analyses and fact-based communications;
l Maintain a focus on the issues related to advancing the science and
research aspects of the biopharmaceutical industry and preserving and
improving an environment supportive of innovation.
1950s 1960s 1970s 1980s 1990s 2000s 2010s/NPC Now
National Pharmaceutical Council
incorporates in New York City (1953)
NPC focuses on educating states about
the problem of unauthorized substitution
of non-FDA-approved products at the
pharmacy level
NPC launches annual pharmacy
internship program with American
Pharmacists Association (1959)

NPC develops Compilation on State
Welfare Drug Programs, which would
later become the annual Pharmaceutical
Benets Under State Medical Assistance
Programs (1963)
NPC moves its headquarters to the
metropolitan Washington, DC area
(1965)
NPC works with states to
examine open drug programs
versus closed formularies;
electronic data processing
systems developed through
this eort were later adapted
by the federal government
and acknowledged in the
publication, Medicaid
Management Information
System
As non-FDA-approved drugs remain a
factor, NPC expands educational eorts
with consumer organizations, medical
and pharmacy students and their related
organizations, and federal agencies
NPC sponsors rst national symposium
on the issue of medication compliance,
featuring then Surgeon General C.
Everett Koop; produces several major
publications and develops widely viewed
public service announcement with
professional tennis player Arthur Ashe
focusing on noncompliance
NPC hosts educational forums to
increase public awareness and
understanding of pharmaceuticals, the
industry, and related issues; to assist
member companies in speaking about
the value of pharmaceuticals, produces
video, Spread the Word, that
receives a Telly Award for excellence in
communications (1993)
NPC launches Managed Care Health
Outcomes Project; ndings suggest
that closed formulary restrictions might
have unintended consequences on the
quality of health outcomes (1996)
NPC hosts rst annual member forum
(1999)
NPC develops research papers focusing
on the contribution of new drugs to
improved health and reduced medical
spending, and on the clinical needs of
subpopulations
NPC launches educational project, Your
Pharmacy Benet, to help consumers
understand, choose and use the
pharmacy benets under private
insurance and Medicare Part D (2006)
NPC turns focus to evidence-based
medicine and comparative eectiveness
research issues; grows sta resources to
address new industry challenges (2007)
NPC continues to expand research
portfolio, partnerships, and unique
capacities in the areas of evidence, value
and innovation
More Than Half a Century of Expertise
NPC Leadership
NPC leadership and sta bring a variety of experience from
within the biopharmaceutical industry, government, health
and regulatory agencies, academia, and advocacy groups to
our work.
Dan Leonard, President, leads NPC in bringing
the biopharmaceutical industrys technical
expertise and applied scientic knowledge to
considerations of evidence-based medicine,
comparative eectiveness reviews, evaluation
and application. A veteran association executive
and communications strategist with more than 20 years
of experience in strategic communications, legislative
management, politics and broadcast journalism, his previous
health care industry experience includes serving as executive
vice president of advocacy and professional services for
Americas Health Insurance Plans (AHIP). He received his
bachelors degree in journalism from Marietta College and a
masters in government from Johns Hopkins University. He
currently serves on several boards and industry committees,
including the Pharmacy and Therapeutics Society, the National
Health Council, and the Health Industry Forum.
Robert W. Dubois, MD, PhD, Chief Science
Ocer, oversees NPCs research on policy issues
related to the harmonization, dissemination, and
communication of comparative eectiveness
research, as well as on how health outcomes are
valued. Dr. Dubois is board certied in internal
medicine and brings more than 25 years of experience in
health services research and comparative clinical eectiveness.
He has co-founded and led health care research organizations
in developing quality research with practical application.
Most recently, he was the chief medical ocer at Cerner
LifeSciences, where he focused on comparative eectiveness
and the use of an electronic health records infrastructure to
implement clinical change. He has authored more than 100
peer-reviewed articles on comparative eectiveness, evidence-
based medicine, the development of practice guidelines, and
the optimal use of high cost medical services. Dr. Dubois
received his AB from Harvard College, his MD from the Johns
Hopkins School of Medicine and his PhD in Health Policy
from the RAND Graduate School.
Patricia L. Adams, Vice President, Business
Operations and External Aairs, is responsible
for the overall operations of NPC, including
member relations, external aairs, educational
programs, and communications. Ms. Adams
works closely with the NPC President and the
scientic sta to ensure the smooth operation of research
activities and educational programs for public and private
payers and health policy makers.

www.npcnow.org
In shaping NPCs research agenda and professional
programming, we access the expertise of health outcomes
researchers, clinicians, market experts, and other industry
leaders. The resulting research and educational events
demonstrate how the appropriate use of biopharmaceuticals
improves both patient treatment and cost outcomes in the
overall health care environment. Our work informs and
supports public and private sector organizations, as well as
eorts to establish and fund a national research agenda.
In carrying out our patient-centric mandate, NPC engages
with a targeted range of stakeholders, focusing on research
standards and methods for evidence generation, interpretation,
and application that will improve patient outcomes while
sustaining and enhancing innovation and the value of
biopharmaceuticals. We collaborate with leading scientic
policy experts from across key health care sectors toward that
goal.
Over the years, we have actively responded to changes in the
biopharmaceutical environment and contributed to informative
research in this arena. As we look to the future, NPC will
continue to anticipate the issues, produce strong, evidence-
based research and education, build new partnerships, and
demonstrate the benets of new medicines to patients and to
society.
Robust Research Agenda
Since its founding more than half a century ago, NPC has
supported a robust research agenda. Over the years the
issues we have focused on have evolved along with changes
and developments in the health care environment and the
biopharmaceutical industry.
NPC believes strongly in the importance of fostering an
environment that sustains and enhances innovation. This
focus on innovation cuts across all streams of NPC-sponsored
research.
Recent research has focused on many of the issues related to
comparative eectiveness research (CER) and building toward
an optimal future for CER. We have compiled much of that
research in a CER Toolkit, which includes information about
the Patient-Centered Outcomes Research Institute (PCORI),
the National Institute for Health and Clinical Excellence (NICE),
as well as The Good ReseArch for Comparative Eectiveness
(GRACE) principles and other documents and studies
examining CER.
NPC also has undertaken studies examining the issues
surrounding ways to ensure more value from medicines.
We are conducting scientic analyses that will enhance
understanding of the overall clinical and economic value
of prescription medications and the contributions of those
medications to improved health and productivity among
patients. Examples include recent studies on Value-Based
Insurance Design, and Health and Productivity as a Business
Strategy, which help employers realize the best value for their
health investments.
NPC-sponsored research publications are available online at
www.npcnow.org/research.
Topical Educational Events
NPCs professional programming advances the public dialogue
by drawing on the biopharmaceutical industrys science
base and expertise as a resource for reducing uncertainty in
care decisions and improving outcomes for patients. Topical
educational events seek to introduce the industrys perspective
and expertise to inform the discussion and generate
momentum around key issues. NPCs Annual Forum, held
each fall in Washington, DC, is a substantive program on issues
of interest to the biopharmaceutical industry and a variety of
health care stakeholders, including patients, clinicians, payers
and policy makers.

NPC educational events include:
Town Hall Meetingsexplore emerging issues of importance
to the biopharmaceutical industry, such as CER and quality
measure development and use, and help member companies
and other health care stakeholders better understand and
translate research ndings into everyday life; some are
videotaped and made available to member companies as
educational tools;
Corporate Roundtablesbrief member companies and key
stakeholders on industry issues, emerging trends, and related
research;
Forums/Symposiumsfeature recognized health care and
biopharmaceutical industry leaders. Recent events include
NPCs Shaping Convergent Strategies in CER: a CER brieng
co-sponsored with Health Aairs; and NPC-sponsored
workshops and symposia on the evaluation, dissemination
and interpretation of CER at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Annual
International Meeting.
NPC often works in partnership with other organizations
among them the Center for Medical Technology Policy
(CMTP), Pragmatic Approaches to Comparative Eectiveness
(PACE), and the Institute for Clinical and Economic Review
(ICER)to contribute strategic and scientic input on critical
issues such as CER. And NPC researchers, members, and sta
also play a key role on professional educational programs
sponsored by other organizations addressing important
stakeholder issues, including the US Chamber of Commerce,
the Health Industry Forum, the National Health Council, and
the Translational Medical Alliance.
OUR APPROACH
NPC is a policy research organization dedicated to the advancement of
good evidence and science, and to fostering an environment in the United
States that supports medical innovation.
NPC focuses on research development, information dissemination,
education and promotion of the critical issues of evidence, innovation and
the value of medicines for patients. The issues we select for examination
and the researchers and academics we partner with position NPC as a
uniquely credible and trusted voice in the biopharmaceutical research and
health policy communities.
NPC is working to:
l Ensure that sound evidence is recognized by independent experts,
considered appropriately by private and public payers, reected
adequately in benet designs, and incorporated into clinical practice;
l Demonstrate and promote the contribution of innovative medicines to
optimizing health and wellness for patients and the entire health care
system through scientic analyses and fact-based communications;
l Maintain a focus on the issues related to advancing the science and
research aspects of the biopharmaceutical industry and preserving and
improving an environment supportive of innovation.
1950s 1960s 1970s 1980s 1990s 2000s 2010s/NPC Now
National Pharmaceutical Council
incorporates in New York City (1953)
NPC focuses on educating states about
the problem of unauthorized substitution
of non-FDA-approved products at the
pharmacy level
NPC launches annual pharmacy
internship program with American
Pharmacists Association (1959)

NPC develops Compilation on State
Welfare Drug Programs, which would
later become the annual Pharmaceutical
Benets Under State Medical Assistance
Programs (1963)
NPC moves its headquarters to the
metropolitan Washington, DC area
(1965)
NPC works with states to
examine open drug programs
versus closed formularies;
electronic data processing
systems developed through
this eort were later adapted
by the federal government
and acknowledged in the
publication, Medicaid
Management Information
System
As non-FDA-approved drugs remain a
factor, NPC expands educational eorts
with consumer organizations, medical
and pharmacy students and their related
organizations, and federal agencies
NPC sponsors rst national symposium
on the issue of medication compliance,
featuring then Surgeon General C.
Everett Koop; produces several major
publications and develops widely viewed
public service announcement with
professional tennis player Arthur Ashe
focusing on noncompliance
NPC hosts educational forums to
increase public awareness and
understanding of pharmaceuticals, the
industry, and related issues; to assist
member companies in speaking about
the value of pharmaceuticals, produces
video, Spread the Word, that
receives a Telly Award for excellence in
communications (1993)
NPC launches Managed Care Health
Outcomes Project; ndings suggest
that closed formulary restrictions might
have unintended consequences on the
quality of health outcomes (1996)
NPC hosts rst annual member forum
(1999)
NPC develops research papers focusing
on the contribution of new drugs to
improved health and reduced medical
spending, and on the clinical needs of
subpopulations
NPC launches educational project, Your
Pharmacy Benet, to help consumers
understand, choose and use the
pharmacy benets under private
insurance and Medicare Part D (2006)
NPC turns focus to evidence-based
medicine and comparative eectiveness
research issues; grows sta resources to
address new industry challenges (2007)
NPC continues to expand research
portfolio, partnerships, and unique
capacities in the areas of evidence, value
and innovation
More Than Half a Century of Expertise
NPC Leadership
NPC leadership and sta bring a variety of experience from
within the biopharmaceutical industry, government, health
and regulatory agencies, academia, and advocacy groups to
our work.
Dan Leonard, President, leads NPC in bringing
the biopharmaceutical industrys technical
expertise and applied scientic knowledge to
considerations of evidence-based medicine,
comparative eectiveness reviews, evaluation
and application. A veteran association executive
and communications strategist with more than 20 years
of experience in strategic communications, legislative
management, politics and broadcast journalism, his previous
health care industry experience includes serving as executive
vice president of advocacy and professional services for
Americas Health Insurance Plans (AHIP). He received his
bachelors degree in journalism from Marietta College and a
masters in government from Johns Hopkins University. He
currently serves on several boards and industry committees,
including the Pharmacy and Therapeutics Society, the National
Health Council, and the Health Industry Forum.
Robert W. Dubois, MD, PhD, Chief Science
Ocer, oversees NPCs research on policy issues
related to the harmonization, dissemination, and
communication of comparative eectiveness
research, as well as on how health outcomes are
valued. Dr. Dubois is board certied in internal
medicine and brings more than 25 years of experience in
health services research and comparative clinical eectiveness.
He has co-founded and led health care research organizations
in developing quality research with practical application.
Most recently, he was the chief medical ocer at Cerner
LifeSciences, where he focused on comparative eectiveness
and the use of an electronic health records infrastructure to
implement clinical change. He has authored more than 100
peer-reviewed articles on comparative eectiveness, evidence-
based medicine, the development of practice guidelines, and
the optimal use of high cost medical services. Dr. Dubois
received his AB from Harvard College, his MD from the Johns
Hopkins School of Medicine and his PhD in Health Policy
from the RAND Graduate School.
Patricia L. Adams, Vice President, Business
Operations and External Aairs, is responsible
for the overall operations of NPC, including
member relations, external aairs, educational
programs, and communications. Ms. Adams
works closely with the NPC President and the
scientic sta to ensure the smooth operation of research
activities and educational programs for public and private
payers and health policy makers.

www.npcnow.org
In shaping NPCs research agenda and professional
programming, we access the expertise of health outcomes
researchers, clinicians, market experts, and other industry
leaders. The resulting research and educational events
demonstrate how the appropriate use of biopharmaceuticals
improves both patient treatment and cost outcomes in the
overall health care environment. Our work informs and
supports public and private sector organizations, as well as
eorts to establish and fund a national research agenda.
In carrying out our patient-centric mandate, NPC engages
with a targeted range of stakeholders, focusing on research
standards and methods for evidence generation, interpretation,
and application that will improve patient outcomes while
sustaining and enhancing innovation and the value of
biopharmaceuticals. We collaborate with leading scientic
policy experts from across key health care sectors toward that
goal.
Over the years, we have actively responded to changes in the
biopharmaceutical environment and contributed to informative
research in this arena. As we look to the future, NPC will
continue to anticipate the issues, produce strong, evidence-
based research and education, build new partnerships, and
demonstrate the benets of new medicines to patients and to
society.
Robust Research Agenda
Since its founding more than half a century ago, NPC has
supported a robust research agenda. Over the years the
issues we have focused on have evolved along with changes
and developments in the health care environment and the
biopharmaceutical industry.
NPC believes strongly in the importance of fostering an
environment that sustains and enhances innovation. This
focus on innovation cuts across all streams of NPC-sponsored
research.
Recent research has focused on many of the issues related to
comparative eectiveness research (CER) and building toward
an optimal future for CER. We have compiled much of that
research in a CER Toolkit, which includes information about
the Patient-Centered Outcomes Research Institute (PCORI),
the National Institute for Health and Clinical Excellence (NICE),
as well as The Good ReseArch for Comparative Eectiveness
(GRACE) principles and other documents and studies
examining CER.
NPC also has undertaken studies examining the issues
surrounding ways to ensure more value from medicines.
We are conducting scientic analyses that will enhance
understanding of the overall clinical and economic value
of prescription medications and the contributions of those
medications to improved health and productivity among
patients. Examples include recent studies on Value-Based
Insurance Design, and Health and Productivity as a Business
Strategy, which help employers realize the best value for their
health investments.
NPC-sponsored research publications are available online at
www.npcnow.org/research.
Topical Educational Events
NPCs professional programming advances the public dialogue
by drawing on the biopharmaceutical industrys science
base and expertise as a resource for reducing uncertainty in
care decisions and improving outcomes for patients. Topical
educational events seek to introduce the industrys perspective
and expertise to inform the discussion and generate
momentum around key issues. NPCs Annual Forum, held
each fall in Washington, DC, is a substantive program on issues
of interest to the biopharmaceutical industry and a variety of
health care stakeholders, including patients, clinicians, payers
and policy makers.

NPC educational events include:
Town Hall Meetingsexplore emerging issues of importance
to the biopharmaceutical industry, such as CER and quality
measure development and use, and help member companies
and other health care stakeholders better understand and
translate research ndings into everyday life; some are
videotaped and made available to member companies as
educational tools;
Corporate Roundtablesbrief member companies and key
stakeholders on industry issues, emerging trends, and related
research;
Forums/Symposiumsfeature recognized health care and
biopharmaceutical industry leaders. Recent events include
NPCs Shaping Convergent Strategies in CER: a CER brieng
co-sponsored with Health Aairs; and NPC-sponsored
workshops and symposia on the evaluation, dissemination
and interpretation of CER at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Annual
International Meeting.
NPC often works in partnership with other organizations
among them the Center for Medical Technology Policy
(CMTP), Pragmatic Approaches to Comparative Eectiveness
(PACE), and the Institute for Clinical and Economic Review
(ICER)to contribute strategic and scientic input on critical
issues such as CER. And NPC researchers, members, and sta
also play a key role on professional educational programs
sponsored by other organizations addressing important
stakeholder issues, including the US Chamber of Commerce,
the Health Industry Forum, the National Health Council, and
the Translational Medical Alliance.
OUR APPROACH
NPC is a policy research organization dedicated to the advancement of
good evidence and science, and to fostering an environment in the United
States that supports medical innovation.
NPC focuses on research development, information dissemination,
education and promotion of the critical issues of evidence, innovation and
the value of medicines for patients. The issues we select for examination
and the researchers and academics we partner with position NPC as a
uniquely credible and trusted voice in the biopharmaceutical research and
health policy communities.
NPC is working to:
l Ensure that sound evidence is recognized by independent experts,
considered appropriately by private and public payers, reected
adequately in benet designs, and incorporated into clinical practice;
l Demonstrate and promote the contribution of innovative medicines to
optimizing health and wellness for patients and the entire health care
system through scientic analyses and fact-based communications;
l Maintain a focus on the issues related to advancing the science and
research aspects of the biopharmaceutical industry and preserving and
improving an environment supportive of innovation.
1950s 1960s 1970s 1980s 1990s 2000s 2010s/NPC Now
National Pharmaceutical Council
incorporates in New York City (1953)
NPC focuses on educating states about
the problem of unauthorized substitution
of non-FDA-approved products at the
pharmacy level
NPC launches annual pharmacy
internship program with American
Pharmacists Association (1959)

NPC develops Compilation on State
Welfare Drug Programs, which would
later become the annual Pharmaceutical
Benets Under State Medical Assistance
Programs (1963)
NPC moves its headquarters to the
metropolitan Washington, DC area
(1965)
NPC works with states to
examine open drug programs
versus closed formularies;
electronic data processing
systems developed through
this eort were later adapted
by the federal government
and acknowledged in the
publication, Medicaid
Management Information
System
As non-FDA-approved drugs remain a
factor, NPC expands educational eorts
with consumer organizations, medical
and pharmacy students and their related
organizations, and federal agencies
NPC sponsors rst national symposium
on the issue of medication compliance,
featuring then Surgeon General C.
Everett Koop; produces several major
publications and develops widely viewed
public service announcement with
professional tennis player Arthur Ashe
focusing on noncompliance
NPC hosts educational forums to
increase public awareness and
understanding of pharmaceuticals, the
industry, and related issues; to assist
member companies in speaking about
the value of pharmaceuticals, produces
video, Spread the Word, that
receives a Telly Award for excellence in
communications (1993)
NPC launches Managed Care Health
Outcomes Project; ndings suggest
that closed formulary restrictions might
have unintended consequences on the
quality of health outcomes (1996)
NPC hosts rst annual member forum
(1999)
NPC develops research papers focusing
on the contribution of new drugs to
improved health and reduced medical
spending, and on the clinical needs of
subpopulations
NPC launches educational project, Your
Pharmacy Benet, to help consumers
understand, choose and use the
pharmacy benets under private
insurance and Medicare Part D (2006)
NPC turns focus to evidence-based
medicine and comparative eectiveness
research issues; grows sta resources to
address new industry challenges (2007)
NPC continues to expand research
portfolio, partnerships, and unique
capacities in the areas of evidence, value
and innovation
More Than Half a Century of Expertise
NPC Leadership
NPC leadership and sta bring a variety of experience from
within the biopharmaceutical industry, government, health
and regulatory agencies, academia, and advocacy groups to
our work.
Dan Leonard, President, leads NPC in bringing
the biopharmaceutical industrys technical
expertise and applied scientic knowledge to
considerations of evidence-based medicine,
comparative eectiveness reviews, evaluation
and application. A veteran association executive
and communications strategist with more than 20 years
of experience in strategic communications, legislative
management, politics and broadcast journalism, his previous
health care industry experience includes serving as executive
vice president of advocacy and professional services for
Americas Health Insurance Plans (AHIP). He received his
bachelors degree in journalism from Marietta College and a
masters in government from Johns Hopkins University. He
currently serves on several boards and industry committees,
including the Pharmacy and Therapeutics Society, the National
Health Council, and the Health Industry Forum.
Robert W. Dubois, MD, PhD, Chief Science
Ocer, oversees NPCs research on policy issues
related to the harmonization, dissemination, and
communication of comparative eectiveness
research, as well as on how health outcomes are
valued. Dr. Dubois is board certied in internal
medicine and brings more than 25 years of experience in
health services research and comparative clinical eectiveness.
He has co-founded and led health care research organizations
in developing quality research with practical application.
Most recently, he was the chief medical ocer at Cerner
LifeSciences, where he focused on comparative eectiveness
and the use of an electronic health records infrastructure to
implement clinical change. He has authored more than 100
peer-reviewed articles on comparative eectiveness, evidence-
based medicine, the development of practice guidelines, and
the optimal use of high cost medical services. Dr. Dubois
received his AB from Harvard College, his MD from the Johns
Hopkins School of Medicine and his PhD in Health Policy
from the RAND Graduate School.
Patricia L. Adams, Vice President, Business
Operations and External Aairs, is responsible
for the overall operations of NPC, including
member relations, external aairs, educational
programs, and communications. Ms. Adams
works closely with the NPC President and the
scientic sta to ensure the smooth operation of research
activities and educational programs for public and private
payers and health policy makers.
The NATIONAL PHARMACEUTICAL COUNCIL (NPC) is the credible and trusted voice of
the biopharmaceutical industry on the critical issues of evidence, the value of medicines for
patients, and innovation.
OUR MISSION
NPCs overarching mission is to sponsor, participate in, and promote scientic analyses
of the appropriate use of biopharmaceuticals, and the clinical and economic value of
improved health outcomes through medical innovation. NPCs strategic focus is on
comparative eectiveness research and evidence-based medicine for health care decision
making, to ensure that patients have access to high-quality care. NPC actively participates
with a variety of health care stakeholders to demonstrate and communicate the value of
biopharmaceuticals and vaccines though practical, evidence-based applications and tools.
NPC is dedicated to:
l Promoting the clinical and economic value of improved health outcomes through
pharmaceutical innovation;
l Contributing to practical solutions that ensure patients have access to and make
appropriate use of prescription medicines;
l Improving health care decision making by expanding the foundation of evidence for
patients and providers to choose treatment options that provide the best clinical value;
and
l Advancing research on the appropriate role of prescription medicines in treating patients.
www.npcnow.org
1894 Preston White Drive
Reston, VA 20191-5433
1501 M Street, NW
Suite 650
Washington, DC 20005
Phone: 703.620.6390
Fax: 703.476.0904
www.npcnow.org
Follow NPC on Twitter @npcnow
Patients
Additional resources available online contain a wealth of information
about the biopharmaceutical industrys most pressing issues.
V
a
l
u
e
I
n
n
o
v
a
t
i
o
n
E
v
i
d
e
n
c
e
www.npcnow.org

website includes a research
and publications library
daily electronic CER update
monthly electronic newsletter